Meeting
2019 ASCO Annual Meeting
Three-year survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM).
Authors
Eddy C. Hsueh
Saint Louis University, St. Louis, MO
Eddy C. Hsueh , James R. DeBloom , Robert W. Cook , Kelly McMasters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02355574/NCT02355587
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9519)
DOI
10.1200/JCO.2019.37.15_suppl.9519
Abstract #
9519
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM).
First Author: David H. Lawson
Poster
2023 ASCO Genitourinary Cancers Symposium
Validation of baseline health-related quality of life as prognostic indicator for survival outcome in men with intermediate risk prostate cancer undergoing radical prostatectomy.
First Author: Thilo Westhofen
Poster
2017 ASCO Annual Meeting
Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head and neck.
First Author: John T. Vetto
Poster
2016 ASCO Annual Meeting
Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients.
First Author: Jonathan S. Zager